Having come under considerable pressure for its manner of detailing medicines to physicians, and with various pieces of legislation to control its activities in the pipeline (Marketletters passim), the US drug industry has come up with its own constraints. These have been generally welcomed by pharmaceutical majors, a significant number of which went to the extent of issuing press statements of their support.
Specifically, their trade body, the Pharmaceutical Research and Manufacturers of America (PhRMA), has issued a revised Marketing Code, which it says is part of an ongoing effort to ensure that pharmaceutical marketing practices comply with the highest ethical standards. Among its changes, the Code:
- prohibits distribution of non-educational items (eg, pens, mugs and other "reminder" objects carrying a company or product logo) to health care providers and their staff. The Code acknowledges that such items, even though of minimal value, "may foster misperceptions" that interactions with health care professionals "are not based on informing them about medical and scientific issues;"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze